The Cooper Companies (COO)
(Delayed Data from NSDQ)
$92.69 USD
+0.08 (0.09%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $93.10 +0.41 (0.44%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$92.69 USD
+0.08 (0.09%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $93.10 +0.41 (0.44%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
Will HSA Member Growth Aid HealthEquity's (HQY) Q3 Earnings?
by Zacks Equity Research
HealthEquity's (HQY) top line is likely to be driven by solid Health Savings Accounts (HSA) member growth in the fiscal third quarter. However, cutthroat competition in the niche space is concerning.
Can Segmental Growth Boost Veeva Systems' (VEEV) Q3 Earnings?
by Zacks Equity Research
Veeva Systems (VEEV) likely to gain from solid segmental show in fiscal Q3; competition stiff.
What's in Store for Patterson Companies' (PDCO) Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal Q2 earnings likely to be marred by a soft Dental unit; Animal Health looks promising.
Why Is Cooper Cos. (COO) Up 5.1% Since Last Earnings Report?
by Zacks Equity Research
Cooper Cos. (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cooper's MiSight Lens Effective in Checking Juvenile Myopia
by Zacks Equity Research
Cooper's (COO) core CVI business gets a boost from MiSight's positive study results.
Cooper Companies (COO) Earnings Miss & Revenues Beat in Q3
by Zacks Equity Research
Cooper (COO) gains from solid CSI revenues in Q3; international revenues surge.
Cooper Cos. (COO) Q3 Earn Earnings ings Lag Estimates
by Zacks Equity Research
Cooper Cos. (COO) delivered earnings and revenue surprises of -2.60% and 1.00%, respectively, for the quarter ended July 2018. Do the numbers hold clues to what lies ahead for the stock?
Cooper Cos. (COO) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Cooper Cos. (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Cooper Companies' (COO) Q3 Earnings?
by Zacks Equity Research
Cooper Companies (COO) is likely to gain from strong segmental show in Q3; a competitive industry raises concern.
Will Medtronic (MDT) Q1 Earnings Show Overall Progress?
by Zacks Equity Research
In Q1, Medtronic (MDT) is expected to have sustained a steady market share across the core pacing, ICD and CRT product lines.
Intuitive Surgical Gains From Solid Q2 and Strong AI Exposure
by Zacks Equity Research
Intuitive Surgical's (ISRG) impressive second-quarter 2018, strength in robotics and AI trends buoy optimism.
CVS Health's PBM Selling Season Strong, Aetna Deal on Track
by Zacks Equity Research
A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.
Amedisys (AMED) Grows on Robust Home Health, Personal Care
by Zacks Equity Research
Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.
Can Cooper Cos. (COO) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Cooper Cos. (COO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Integra LifeSciences Codman Arm Strong, Competition Rife
by Zacks Equity Research
Integra LifeSciences' (IART) progress within its channel expansion strategy and Codman integration buoys investors' optimism on the stock.
Inogen's Solid Europe Business Shapes Q2, Prospects Bright
by Zacks Equity Research
Inogen's (INGN) Europe performance solid in Q2; guidance for 2018 encourages.
Surmodics' (SRDX) IVD Unit Boosts Growth, R&D Focus Solid
by Zacks Equity Research
Surmodics' (SRDX) strong focus on R&D to provide it a competitive edge in the MedTech space.
Boston Scientific to Expand Within PI Via VENITI Buyout
by Zacks Equity Research
Presence of venous obstructive disease visibly grows across the globe, indicating huge prospects for Boston Scientific (BSX) in the treatment market.
Here's Why You Should Dump DENTSPLY (XRAY) Stock Right Now
by Zacks Equity Research
DENTSPLY (XRAY) incurs goodwill and intangible impairment charge. A lowered guidance is a concern.
Here's Why You Should Hold on to Ecolab (ECL) Stock Now
by Zacks Equity Research
Ecolab (ECL) is likely to gain from a robust product portfolio, new product launches and expanding customer base.
Varian Acquires humediQ, Boosts Motion Management Portfolio
by Zacks Equity Research
Varian (VAR) incorporates humediQ's coveted IDENTIFY technology in its comprehensive suite of oncology solutions.
COO or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COO vs. MMSI: Which Stock Is the Better Value Option?
What's in Store for Pacific Biosciences' (PACB) Q2 Earnings?
by Zacks Equity Research
Pacific Biosciences' (PACB) flagship Sequel System is likely to drive Q2 results; competition is a headwind.
Can Kidney Care Business Drive DaVita's (DVA) Q2 Earnings?
by Zacks Equity Research
DaVita's (DVA) flagship Kidney Care business likely to drive Q2 results; solid international presence encourages.
Why Cardinal Health (CAH) Could Be Positioned for a Slump
by Zacks Equity Research
Cardinal Health (CAH) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.